Dr. Kaveh Hoda

This is such a recurring theme with pharmaceutical companies. I just did an episode about a medication called Zygris. which was, wow, it sounds like the Tigris. It sounds awesome. It sounds awesome. It's this medication that was touted as like this new breakthrough therapy for sepsis. And it was super exciting.

This is such a recurring theme with pharmaceutical companies. I just did an episode about a medication called Zygris. which was, wow, it sounds like the Tigris. It sounds awesome. It sounds awesome. It's this medication that was touted as like this new breakthrough therapy for sepsis. And it was super exciting.

It ended up falling apart for a lot of different reasons and being withdrawn and then being a big marketing scandal, in my opinion. But at the end of the day, it all started because they were losing their patent on their big like sellings and medications. Like the one, the things that were making them tons of money were about to run out and they needed a new like cash stream as quick as possible.

It ended up falling apart for a lot of different reasons and being withdrawn and then being a big marketing scandal, in my opinion. But at the end of the day, it all started because they were losing their patent on their big like sellings and medications. Like the one, the things that were making them tons of money were about to run out and they needed a new like cash stream as quick as possible.

It ended up falling apart for a lot of different reasons and being withdrawn and then being a big marketing scandal, in my opinion. But at the end of the day, it all started because they were losing their patent on their big like sellings and medications. Like the one, the things that were making them tons of money were about to run out and they needed a new like cash stream as quick as possible.

So things started happening probably faster than they should have.

So things started happening probably faster than they should have.

So things started happening probably faster than they should have.

Right. And when the money starts to shift from research and development in these companies to marketing, which it does more and more.

Right. And when the money starts to shift from research and development in these companies to marketing, which it does more and more.

Right. And when the money starts to shift from research and development in these companies to marketing, which it does more and more.

Yeah, I'm assuming that's the problem here.

Yeah, I'm assuming that's the problem here.

Yeah, I'm assuming that's the problem here.

Oh, I'm the people who deserve to.

Oh, I'm the people who deserve to.

Oh, I'm the people who deserve to.

Yeah, the Vagelos Award is like this award that's still given out to people who are doing humanitarian work in the pharmaceutical world. So this is a major shift, a major shift away from somebody who was, I think, ostensibly a very good person from all accounts, a very good person, a good researcher, to something very different. Yeah.

Yeah, the Vagelos Award is like this award that's still given out to people who are doing humanitarian work in the pharmaceutical world. So this is a major shift, a major shift away from somebody who was, I think, ostensibly a very good person from all accounts, a very good person, a good researcher, to something very different. Yeah.

Yeah, the Vagelos Award is like this award that's still given out to people who are doing humanitarian work in the pharmaceutical world. So this is a major shift, a major shift away from somebody who was, I think, ostensibly a very good person from all accounts, a very good person, a good researcher, to something very different. Yeah.